AegirBio avger delårsrapport och redogör för väsentliga händelser

​​​​​​

SAMMANFATTNING ANDRA KVARTALET

Andra kvartalet jämfört med samma period 2022

• Totala intäkter uppgick till 0 (0) MSEK
• Resultatet före skatt uppgick till -16,4 (-18,0) MSEK, varav 1,5 MSEK är kostnader av engångskaraktär. Det innebär en total förbättring om 1,6 MSEK vilket visar att besparings- och effektiviseringsåtgärderna så smått börjar ge effekt i andra kvartalet.
• Kassabehållningen var vid slutet av kvartalet 36,6 (7,4) MSEK efter erhållen likvid om totalt 46,3 MSEK i första kvartalet till följd av utnyttjande av teckningsoptioner och konvertibellånet från Atlas.

Första halvåret 2023 jämfört med 2022

• Totala intäkter uppgick till 0 (1,4) MSEK
• Resultatet före skatt uppgick till -31,9 (-32,3)
• Resultat per aktie* uppgick till -1,06 (-1,73)
• Soliditeten** uppgick till 31%
• Resultat per aktie* uppgick till -1,06 (-1,73) SEK

* Resultat per aktie: Periodens resultat dividerat med vägt genomsnittligt antal aktier som per 2023-06-30 uppgick till 25 876 872 aktier före utspädning. Motsvarande siffra för samma period föregående år var 17 324 062 aktier.

** Soliditet: Eget kapital dividerat med totalt kapital.

VÄSENTLIGA HÄNDELSER UNDER OCH EFTER PERIODENS UTGÅNG

• AegirBio AB stärker upp organisationen genom Marco Witteveen som CEO från den 15 juni. Marco har mer än 30 års erfarenhet av MedTech bolag, varav 20 år med fokus på Point of Care diagnostik på global nivå. 

· AegirBio sluter ett icke exklusivt avtal med Salofa Oy för veterinärmarknaden och får en första order på c:a 2 MSEK. Avtalet ger Salofa Oy rätt att sälja vår MagniaReader till veterinärmarknaden.

· AegirBio AB har fått programmatiskt godkännande av National Institutes of Health (NIH) för ett tillgänglighetsprojekt. I den första fasen av projektet kan företaget erhålla upp till cirka 1 miljon USD i milstolpsbaserade betalningar med potential för uppföljnings-finansiering om vissa milstolpar som demonstrerar projektets genomförbarhet uppnås. Finansiering är beroende av uppnåendet av de uppställda milstolparna.

Marco Witteveen - CEO

How I joined AegirBio as the new CEO

In April I was asked by the Board of Directors to perform a detailed assessment of the whole AegirBio group including organization, technologies and plans for commercialization of products that AegirBio developed. This was just after the threat of delisting had been avoided. Board and management were both looking for the way forward as a company with solid technology in Point of Care (PoC) testing and a plan to take this all the way to home testing. Home testing, with an affordable instrument platform would be a game changer for the company.

My background in some of the biggest companies in PoC testing has made me think that the science behind the development of products is crucial, but how to use the science to develop the best possible products for the market is just as important. This requires a clear business plan and focus already on development.

After talking to the key management and the board, presenting the result of my assessment of the group, I was offered the position as CEO which I accepted.

Since coming on board

I have visited AegirBio's sites in Sweden, Finland, UK and USA. There are different challenges in the different sites, however the first steps to a market-focused development have been taken, more on that below. As you have seen the challenge in the financial department with the turnover of CFOs has led to criticism but with the recent change on the position, I feel comfortable that this is now resolved. Anyway, I will get back to you in September with a more detailed presentation on how the company will move forward.

Some exciting news

· I am very happy that we have signed a contract with Salofa for veterinary applications using our technology and instrumentation. Salofa is very familiar with test development for veterinary tests on the MagniaReader and this is an opportunity to commercialize the technology in an area which is not competing with AegirBio's core business.

· In addition, the contract with the US governmental organization, National Institute of Health (NIH), makes me both happy and proud. The team in USA and UK have presented our solution for making advanced testing available in-home setting. The format of our solution makes it accessible also for people who normally have difficulties to perform tests themselves. For this reason, the NIH has given us a contract to develop such a platform. I think this is a clear signal of the value of our technologies and the power of the organization.

Finances

During the past 12 months, a lot of the management’s time and resources have been spent on focusing on items other than the operations. I trust that this time now is behind us and that we can focus on developing and preparing to bring products to the market. We are well financed for the development of the new home testing platform, and, with the NIH contract, we can now increase the speed of these projects.

Structure

The structure has been redefined. So, our US subsidiary will focus on the scientific and market research part of the work, and we are increasing our staff there. The R&D focus will take place from our UK subsidiary, we have hired more lab space and are also expanding our team there to support the NIH program. The Finnish subsidiary will continue to support and grow the veterinary side of our business as we have the agreement with Salofa in place.

Direction

Moving forward, our key focus is the NIH project and reaching that key milestone which is to develop a prototype multiplex platform for home-use that can measure both Covid-19 and Influenza. In parallel we will continue to develop our first Therapeutic Drug Monitoring product, also for home-use, utilizing that same platform. On top of that, our scientific team is investigating a potential direct-to-consumer product to add to our core strategy. As time-to-market has our overall attention and we don't want to exclude any option we have at this stage.

Denna information är sådan som AegirBio är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning (EU nr 596/2014). Informationen lämnades, genom angiven kontaktpersons försorg, för offentliggörande 2023-08-25 08:30 CET.